Seattle genetics to host conference call and webcast discussion of fourth quarter and full year 2018 financial results on february 7, 2019

Bothell, wash.--(business wire)--seattle genetics, inc. (nasdaq: sgen) announced today that it will report its fourth quarter and full year 2018 financial results on thursday, february 7, 2019 after the close of financial markets. following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. access to the event can be obtained as follows: live access on thursday, february 7, 20191:30 p.m. pacific time / 4:30 p.m. eastern time telephone 877-260-1479 (domestic) or +1 334-323-0522 (international); conference id 1660553 webcast available at www.seattlegenetics.com in the investors section replay access telephone replay will be available beginning at approximately 4:30 p.m. pt on thursday, february 7, 2019 through 5:00 p.m. pt on monday, february 11, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference id 1660553 webcast replay will be available on the seattle genetics website at www.seattlegenetics.com in the investors section about seattle genetics seattle genetics, inc. is an emerging multi-product, global biotechnology company that develops and commercializes transformative therapies targeting cancer to make a meaningful difference in people’s lives. adcetris® (brentuximab vedotin) utilizes the company’s industry-leading antibody-drug conjugate (adc) technology and is currently approved for the treatment of multiple cd30-expressing lymphomas. beyond adcetris, the company has established a pipeline of novel targeted therapies at various stages of clinical testing, including three in ongoing pivotal trials for solid tumors. enfortumab vedotin for metastatic urothelial cancer and tisotumab vedotin for metastatic cervical cancer utilize our proprietary adc technology. tucatinib, a small molecule tyrosine kinase inhibitor, is in a pivotal trial for her2-positive metastatic breast cancer. in addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents in clinical trials targeting hematologic malignancies and solid tumors. the company is headquartered in bothell, washington, and has a european office in switzerland. for more information on our robust pipeline, visit www.seattlegenetics.com and follow @seattlegenetics on twitter.
SGEN Ratings Summary
SGEN Quant Ranking